GlassScriptPhysician profile
Marco A Katada
NPI 1003224932
$11,690.56
in general payments reported to CMS, 2019-2025
32 companies · $3,693 in 2025
The $3,693 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,274 · 2022: $2,032 · 2023: $1,962 · 2024: $2,730 · 2025: $3,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,285 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,285.41 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,596.24 | 2021-2025 | Ingrezza |
| Abbvie INC. | $1,321.50 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,149.97 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,008.07 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $965.18 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $831.35 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $758.29 | 2021-2025 | Rexulti, Abilify Asimtufii, Brintellix |
| Janssen Pharmaceuticals, INC | $570.74 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $440.38 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $390.07 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $306.41 | 2024-2025 | Auvelity |
| Bausch Health US, LLC | $269.33 | 2022-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $231.83 | 2021-2025 | Fanapt |
| Merck Sharp & Dohme LLC | $213.26 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $198.14 | 2021-2025 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $198.09 | 2023-2025 | Secuado, Xelstrym |
| Sunovion Pharmaceuticals INC. | $152.78 | 2021-2022 | |
| Almatica Pharma LLC | $120.27 | 2023-2024 | Loreev Xr |
| Alfasigma USA, INC. | $118.49 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $117.74 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $116.86 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $115.67 | 2022-2024 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $107.01 | 2022 | |
| Supernus Pharmaceuticals, INC. | $85.71 | 2022-2024 | Qelbree, Qelbree |
| Indivior INC. | $81.30 | 2024 | Perseris |
| Tris Pharma INC | $65.24 | 2022-2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $54.11 | 2021 | |
| Eisai INC. | $34.45 | 2021 | |
| Collegium Pharmaceutical, INC. | $33.56 | 2025 | Jornay Pm |
| Orexo US, INC. | $20.22 | 2021 | |
| Pear Therapeutics (US), INC. | $14.24 | 2021 | |
| Janssen Biotech, INC. | $4.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Katada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.